Literature DB >> 12218575

Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens.

Siobhan A Nicholson1, Mary Beth Beasley, Elizabeth Brambilla, Philip S Hasleton, Thomas V Colby, Mary N Sheppard, Roni Falk, William D Travis.   

Abstract

Separation of small cell lung carcinoma (SCLC) from nonsmall cell lung carcinoma (NSCLC) is a critical distinction to be made in the diagnosis of lung cancer. However, the diagnosis of SCLC is most commonly made on small biopsies and cytologic specimens, and practicing pathologists may not be familiar with all its morphologic guises and frequent combination with NSCLC elements, which may be seen in larger specimens. Following the most recent WHO classification of lung tumors and with the hope of identifying prognostic markers, we examined in detail the histology of 100 surgical biopsies or resections with a diagnosis of SCLC from the AFIP and pathology panel of the International Association for the Study of Lung Cancer (IASLC). Multiple clinical and histologic features were studied by Kaplan-Meier analysis. Neuroendocrine architectural patterns, including nested and trabecular growth, with peripheral palisading and rosette formation were common in SCLC. Necrosis and apoptotic debris was prominent in all cases, but crush artifact was infrequent. Cell size in surgical biopsy specimens appears larger than in bronchoscopic biopsy specimens and occasional cells may show prominent nucleoli and vesicular nuclear chromatin, but this does not preclude the diagnosis of SCLC. A high percentage of cases (28%) showed combinations with NSCLC, with large cell carcinoma the most common, followed by adenocarcinoma and squamous cell carcinoma. Because of the frequency of a few scattered large cells in SCLC, we arbitrarily recommend that at least 10% of the tumor show large cell carcinoma before subclassification as combined SC/LC. However, combined SCLC is easily recognized if the additional component consists of other NSCLC subtypes such as adenocarcinoma or squamous cell carcinoma, so no percentage requirement is needed. Stage remained the only predictor of prognosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218575     DOI: 10.1097/00000478-200209000-00009

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  97 in total

1.  Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer.

Authors:  Tomomi Nobashi; Sho Koyasu; Yuji Nakamoto; Takeshi Kubo; Takayoshi Ishimori; Young H Kim; Akihiko Yoshizawa; Kaori Togashi
Journal:  Br J Radiol       Date:  2016-01-12       Impact factor: 3.039

2.  TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

Authors:  Charles C Guo; Jane Y Dancer; Yan Wang; Ana Aparicio; Nora M Navone; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2010-10-30       Impact factor: 3.466

Review 3.  Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

Authors:  Stefano La Rosa; Fausto Sessa; Silvia Uccella
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

4.  Elevated RABEX-5 protein expression predicts poor prognosis in combined small cell lung cancer.

Authors:  Fuliang Zhang; Meng Zhang; Guohua Hu; Qiling Cai; Tongbai Xu
Journal:  Tumour Biol       Date:  2015-05-23

5.  Combined small cell carcinoma with giant cell carcinoma component of the lung: A case successfully diagnosed by computed tomography-guided fine-needle aspiration cytology.

Authors:  Yusuke Ebisu; Mitsuaki Ishida; Tomohito Saito; Tomohiro Murakawa; Yoshiko Uemura; Koji Tsuta
Journal:  Oncol Lett       Date:  2017-11-20       Impact factor: 2.967

Review 6.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

7.  Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer.

Authors:  Man Qiao; Guohua Hu
Journal:  Tumour Biol       Date:  2015-04-25

8.  Targeted therapies in small cell lung cancer.

Authors:  Hong-Yang Lu; Xiao-Jia Wang; Wei-Min Mao
Journal:  Oncol Lett       Date:  2012-07-06       Impact factor: 2.967

Review 9.  Cellular and molecular biology of small cell lung cancer: an overview.

Authors:  Niki Karachaliou; Sara Pilotto; Chiara Lazzari; Emilio Bria; Filippo de Marinis; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 10.  The clinical utility of circulating tumour cells in patients with small cell lung cancer.

Authors:  Victoria Foy; Fabiola Fernandez-Gutierrez; Corinne Faivre-Finn; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.